Federal Register #DEA-499

DEA Final Rule Expanding Medication-Assisted Treatment for Opioid Use Disorder

This final rule from the Drug Enforcement Administration (DEA) implements legislative changes related to medication-assisted treatment (MAT) for opioid use disorder: - Government Buyer: - Department of Justice (DOJ) - Drug Enforcement Administration (DEA) - No OEMs or commercial vendors are named; this is a regulatory update, not a procurement action - No products, part numbers, or quantities are requested - Notable requirements and changes: - Expands the ability of practitioners to provide MAT for opioid use disorder - Permits pharmacies to deliver prescribed controlled substances to practitioners' registered locations for maintenance or detoxification treatment - Aligns DEA regulations with the SUPPORT Act and the Restoring Hope for Mental Health and Well-Being Act - Broadens practitioner eligibility and delivery options for controlled substances used in MAT - No procurement or acquisition of goods or services is involved

Description

The SUPPORT Act, enacted on October 24, 2018, amended the Controlled Substances Act to expand conditions for medication-assisted treatment for opioid use disorder, including provisions for pharmacies to deliver controlled substances for maintenance or detoxification treatments. The DEA issued an interim final rule in November 2020 to implement these provisions, which is now finalized with minor modifications, and also incorporates provisions from the 2022 Restoring Hope for Mental Health and Well-Being Act. This final rule aligns DEA regulations with recent legislative changes to facilitate medication-assisted treatment for opioid use disorder.

View original listing